ARWR Stock: Price, Earnings History and SEC Filings
Arrowhead Pharmaceuticals, Inc. (ARWR) last traded at $59.90, down 0.98% on the latest session and down 8.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.36 against an analyst estimate of $-1.23, a miss of 10.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ARWR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-1.36 | $-1.23 | -10.57% |
| Mar 2026 | May 7, 2026 | $-0.93 | $-1.18 | +21.19% |
| Dec 2025 | Feb 5, 2026 | $0.22 | $0.60 | -63.33% |
| Sep 2025 | Nov 25, 2025 | $-0.18 | $0.12 | -250.00% |
ARWR beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How ARWR reacts to earnings
Across its last 8 earnings releases, ARWR moved 9.3% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | -2.99% |
| 2026-05-07 | After close | -6.75% |
| 2026-02-05 | After close | -0.19% |
| 2025-11-25 | After close | +23.34% |
| 2025-08-07 | After close | +2.24% |
| 2025-05-12 | After close | +9.38% |
| 2025-02-10 | After close | -5.17% |
| 2024-11-26 | After close | +24.23% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ARWR financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $829M | -$2M | $157M | -0.2% | $-0.01 |
| 2024 | $4M | -$599M | -$604M | -16882.4% | $-5.00 |
| 2023 | $241M | -$205M | -$331M | -85.3% | $-1.92 |
| 2022 | $243M | -$176M | -$189M | -72.4% | $-1.67 |
| 2021 | $138M | -$141M | $148M | -101.9% | $-1.36 |
| 2020 | $88M | -$85M | -$108M | -96.1% | $-0.84 |
| 2019 | $169M | $68M | $161M | 40.3% | $0.69 |
| 2018 | $16M | -$54M | -$49M | -337.3% | $-0.65 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ARWR
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 4, 2026
- 8-K · Jun 16, 2026Officer or director change, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 8-K · Mar 20, 2026Shareholder vote, Financial statements and exhibits
- 10-Q · Feb 5, 2026
- 8-K · Feb 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Jan 27, 2026
- 8-K · Jan 12, 2026Material agreement, New financial obligation, Financial statements and exhibits
Insider filing activity
ARWR insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ARWR news
- 3 Biotech Stocks With Upside Of Up To 80%Oct 31, 2026 · finance.yahoo.com
- Arrowhead gains UK marketing authorisation for RedemploOct 28, 2026 · pharmaceutical-technology.com
- Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce TriglyceridesOct 27, 2026 · finance.yahoo.com
- Arrowhead Pharmaceuticals And 2 Biotech Stocks To OwnOct 24, 2026 · finance.yahoo.com
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in September.